![]() Results showed clinical pregnancy rates for Milprosa™ were similar to progesterone gel, regardless of the day the embryos were returned to the uterus. These data were presented as an oral presentation at the 68 th Annual Meeting of the American Society for Reproductive Medicine (ASRM).ĭata from a randomized, single-blind trial assessing the pregnancy rate of Milprosa™ versus daily 8 percent progesterone gel for luteal supplementation in women undergoing embryo transfer during IVF at days three and five were presented. ( NYS: TEVA), today announced findings from a Phase III clinical trial of Milprosa TM (progesterone), an investigational weekly progesterone vaginal ring for luteal supplementation in women undergoing in vitro fertilization (IVF). Data Demonstrates Efficacy of the Vaginal Progesterone Ring, Milprosa™, is Similar to Progesterone Gel and May Offer a Convenient Administration Route for Women -įRAZER, Pa.-( BUSINESS WIRE)- Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. ![]() Announces New Data on Phase III Investigational Progesterone Vaginal Ring at the 68 th Annual Meeting of the American Society for Reproductive Medicine
0 Comments
Leave a Reply. |